BeyondSpring Inc.
BYSI
Rank in Stocks
#25527
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on... BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
Share Price
$0.617
Last synced: 2026-11-09
Market Cap
$25.37M
Change (1 day)
-1.44%
Change (1 year)
-71.95%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade BeyondSpring Inc. (BYSI)
Category
Healthcare
Operating Margin for BeyondSpring Inc. (BYSI)
Operating Margin as of November 2026 TTM: 0.00%
According to BeyondSpring Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for BeyondSpring Inc. from 2014 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -2,756.40% | -43.78% |
| 2021 | -4,903.03% | -86.26% |
| 2020 | -35,672.78% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about BeyondSpring Inc.'s operating margin
What was BeyondSpring Inc.'s operating margin in 2025?
In 2025, BeyondSpring Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has BeyondSpring Inc.'s operating margin changed since 2020?
From 2020 to 2025, BeyondSpring Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2020 (-35,672.78%).
How does BeyondSpring Inc.'s operating margin compare with similar companies?
BeyondSpring Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.